BiomX Inc. (PHGE-UN)
USD 0.04
(-4.19%)
USD 0.04
(-4.19%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 55.07 Million USD | 124.87% |
| 2022 | 24.49 Million USD | -19.58% |
| 2021 | 30.45 Million USD | 136.2% |
| 2020 | 12.89 Million USD | 68.22% |
| 2019 | 7.66 Million USD | 203.2% |
| 2018 | 2.52 Million USD | 2.76% |
| 2017 | 2.46 Million USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 41.19 Million USD | -29.86% |
| 2024 Q1 | 58.73 Million USD | 6.64% |
| 2023 FY | 55.07 Million USD | 124.87% |
| 2023 Q3 | 24.9 Million USD | -1.91% |
| 2023 Q1 | 25.26 Million USD | 3.14% |
| 2023 Q2 | 25.38 Million USD | 0.5% |
| 2023 Q4 | 55.07 Million USD | 121.17% |
| 2022 Q4 | 24.49 Million USD | -3.36% |
| 2022 FY | 24.49 Million USD | -19.58% |
| 2022 Q3 | 25.34 Million USD | -1.17% |
| 2022 Q2 | 25.64 Million USD | -10.73% |
| 2022 Q1 | 28.72 Million USD | -5.68% |
| 2021 Q1 | 13.1 Million USD | 1.66% |
| 2021 Q4 | 30.45 Million USD | 7.34% |
| 2021 Q3 | 28.37 Million USD | 117.29% |
| 2021 Q2 | 13.05 Million USD | -0.39% |
| 2021 FY | 30.45 Million USD | 136.2% |
| 2020 Q3 | 9.31 Million USD | 94.51% |
| 2020 Q1 | 5.46 Million USD | -28.74% |
| 2020 Q4 | 12.89 Million USD | 38.42% |
| 2020 FY | 12.89 Million USD | 68.22% |
| 2020 Q2 | 4.78 Million USD | -12.32% |
| 2019 Q4 | 7.66 Million USD | 920.48% |
| 2019 Q3 | 751.11 Thousand USD | -13.76% |
| 2019 Q2 | 871.01 Thousand USD | 32.04% |
| 2019 Q1 | 659.63 Thousand USD | 26.52% |
| 2019 FY | 7.66 Million USD | 203.2% |
| 2018 Q3 | 91 Thousand USD | 0.0% |
| 2018 FY | 2.52 Million USD | 2.76% |
| 2018 Q4 | 521.37 Thousand USD | 472.89% |
| 2017 FY | 2.46 Million USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| AIM ImmunoTech Inc. | 9.14 Million USD | -502.11% |
| Ampio Pharmaceuticals, Inc. | 2.37 Million USD | -2217.971% |
| Armata Pharmaceuticals, Inc. | 142.02 Million USD | 61.223% |
| Actinium Pharmaceuticals, Inc. | 45.06 Million USD | -22.21% |
| Azitra, Inc. | 2.2 Million USD | -2400.749% |
| Can-Fite BioPharma Ltd. | 3.74 Million USD | -1370.235% |
| Chromocell Therapeutics Corporation | 6.54 Million USD | -742.004% |
| Calidi Biotherapeutics, Inc. | 18.25 Million USD | -201.715% |
| CEL-SCI Corporation | 17.31 Million USD | -218.107% |
| iBio, Inc. | 7.41 Million USD | -643.252% |
| Lineage Cell Therapeutics, Inc. | 38.99 Million USD | -41.232% |
| MAIA Biotechnology, Inc. | 7.08 Million USD | -676.871% |
| Matinas BioPharma Holdings, Inc. | 46.33 Million USD | -18.87% |
| Navidea Biopharmaceuticals, Inc. | 12.51 Million USD | -340.075% |
| NovaBay Pharmaceuticals, Inc. | 5.72 Million USD | -862.85% |
| NanoViricides, Inc. | 1.35 Million USD | -3953.28% |
| Oragenics, Inc. | 1.79 Million USD | -2962.817% |
| BiomX Inc. | 55.07 Million USD | 0.0% |
| Protalix BioTherapeutics, Inc. | 50.86 Million USD | -8.277% |
| Palatin Technologies, Inc. | 10.85 Million USD | -407.428% |
| Scorpius Holdings, Inc. | 22.74 Million USD | -142.159% |
| Theriva Biologics, Inc. | 20.51 Million USD | -168.475% |